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Hassan Khan,1 Shilpa Oberoi,1 Armeen Mahvash,2 Manish Sharma,1 Gabriela Rondon,1
Amin Alousi,1 Elizabeth J. Shpall,1 Dimitrios P. Kontoyiannis,3
Richard E. Champlin,1 Stefan O. Ciurea1BK virus (BKV) is a human polyomavirus that remains latent in the urinary tract epithelium in most indi-
viduals. However, in immunocompromised states, including after hematopoietic stem cell transplantation
(HSCT), BKV may reactivate and cause infection predominantly affecting the bladder, commonly mani-
fested as hemorrhagic cystitis. Renal insufficiency, occasionally requiring hemodialysis, is not uncommon
and was previously attributed to medications or the development of tubulointestitial nephritis. We report
a series of 6 HSCT recipients who developed obstructive uropathy of the upper urinary tract system sec-
ondary to inflammation and hemorrhage involving the upper uroepithelium, causing ureteral stenosis. Tem-
porary placement of a percutaneous nephrostomy catheter relieved the obstruction and significantly
improved kidney function, successfully preventing progression to more advanced renal disease in these
patients.
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BK virus (BKV) is a human polyomavirus infec-
ting approximately 60%-80% of the adult human
population. Most individuals remain seropositive and
asymptomatic throughout the lifespan; however, in
immunocompromised states, including after hemato-
poietic stem cell transplantation (HSCT), the virus
may become reactivated, causing primarily BKV-
associated hemorrhagic cystitis [1]. More rarely, BKV
infection can present or progress to tubulointerstitial
nephritis, complicating treatment outcomes [2].
Several reports have documented direct kidney
injury from BKV in immunosupressed solid organ
transplantation and HSCT recipients [3-9]. Most
cases of BKV nephropathy have been reported in
renal transplant recipients, and the risk factors for1Department of Stem Cell Transplantation and Cellular
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cystitis or nephropathy are incompletely defined [10].
Non‒renal transplant recipients receive similar immu-
nosuppressive regimens as kidney transplant recipi-
ents, including calcineurin inhibitors, which might
account for, at least in part, the renal dysfunction
observed in these patients.
There is no established therapy for BKV infection.
Intravenous or intravesicular cidofovir and lefluno-
mide have in vitro BKV inhibitory activity; however,
cidofovir is highly nephrotoxic, and leflunomide is
hepatotoxic and is rarely tolerated at full doses after
HSCT because of its myelosuppressive adverse effects
[11]. More commonly, treatment is symptomatic and
includes pain control, antispasmodics, platelet transfu-
sions to limit associated hematuria, and continuous
bladder irrigation to prevent ureteral obstruction
from blood clots [12].
We hypothesize that kidney dysfunction in pa-
tients with BKV cystitis may result from obstructive
uropathy involving the upper urinary tract system,
and suggest that temporary nephrostomy catheter
placement may relieve the obstruction and improve
kidney function in these patients.
PATIENTS AND METHODS
Selection of Patients
A retrospective chart review was undertaken of all
HSCT patients who developed BKV cystitis treated in
1552 Biol Blood Marrow Transplant 17:1546-1568, 2011H. Khan et al.the Department of Stem Cell Transplantation and
Cellular Therapy of the University of Texas M.D.
Anderson Cancer Center between March 2009 and
February 2010. A total of 421 patients underwent
allogeneic HSCT during this period (including trans-
plants from matched related, matched unrelated, cord
blood, and haploidentical donors), of whom 87 (21%)
developed BKV cystitis. The presence of BKV in the
urine was confirmed by quantitative polymerase chain
reaction (PCR), with results reported as the number of
viral copies/mL. Detection of any virus in the urine
was considered a positive test result. Six patients who
demonstrated a significant increase in creatinine level
(ie, doubling from baseline levels) or a.50% decrease
in creatinine clearance underwent evaluation for ob-
structive uropathy and had a temporary nephrostomy
catheter placed to relieve obstruction. A data review
protocol that included a waiver of informed consent
was approved by theUniversity of TexasM.D. Anderson
Cancer Center’s Institutional Review Board for this
study.
Definitions
Engraftment was defined as achieving an absolute
neutrophil count of.0.5 109/L for at least 3 consec-
utive days before day 28 post-HSCT, with donor-
derived cells detected by DNA microsatellite analysis.
Myeloablative conditioning was defined as regimens
including busulfan .520 mg/m2, melphalan .140
mg/m2, or total body irradiation.6Gy, with doses be-
low these values considered reduced-intensity condi-
tioning [13]. Acute graft-versus-host disease (aGVHD)
was defined and graded according to previously de-
scribed criteria [14]. BKV infection was diagnosed if
typical symptoms of hemorrhagic cystitis (ie, dysuria,
urinary frequency, hematuria, bladder pain/spasms)
were associated with a positive PCR for BKV in the
urine of the transplant recipient.
Statistical Analysis
Data were double-entered and analyzed in Stata
11.0 (StataCorp, College Station, TX) and Microsoft
Excel (Microsoft Corp, Redmond, WA) on February
22, 2011. Results are presented as median (range)
frequencies.RESULTS
Characteristics of the patients and treatment out-
comes are summarized in Table 1. Transplantation
was performedmostly for acute and chronic leukemias,
with grafts fromunrelated donors (in 4 patients) or cord
blood (in 2 patients). Three patients had a reduced-
intensity conditioning regimen, and the other 3 patients
received myeloablative conditioning (Table 1). All pa-
tients received anti-thymocyte globulin. The medianfollow-up for survivors (n 5 4) was 608 days (range,
440-715 days). All patients achieved remission after
HSCT, and only 1 patient (with acute myeloid leuke-
mia) relapsed. Four patients developed grade II-IV
aGVHD, andnone developed chronicGVHD.Thepa-
tients with aGVHDwere treatedwith systemic cortico-
steroids, with therapy tapered and then discontinued
after the resolution of GVHD. Two patients died, at
64 and 177 days post-HSCT, due to recurrence of pri-
mary disease and multiorgan failure, respectively.
Six patients (7%) with documented BKV infection
demonstrated an elevated serum creatinine level and
were evaluated for obstructive uropathy.These patients
underwent temporary nephrostomy tube placement by
an interventional radiologist. BKV viruria was detected
by PCR at a median of 36 days post-HSCT (range, 12-
67 days). The median number of viral copies was 119
million/mL (range, 30-500 million/mL). Two out of 3
tested patients were also positive for adenovirus. The
earliest and most common symptom was dysuria (pres-
ent in all 6 patients); hematuria, which occurred initially
in 5 patients, was the second most common complaint.
Other symptoms included urgency/frequency in 4 pa-
tients and flank pain in 3 patients.
All patients were initially managed with continu-
ous bladder irrigation. Those patients presenting
with excessive hematuria and blood clots received in-
travesical formalin or bladder fulguration in an at-
tempt to achieve hemostasis. Other conservative
strategies involved antiviral therapy, such as intrave-
nous cidofovir in 4 patients, and hyperbaric oxygen
therapy (100% oxygen concentration at 2 atmospheric
absolute pressures for 60minutes a day) in 2 patients. If
a patient developed upper urinary tract symptoms (eg,
flank pain) and/or a doubling of serum creatinine level
over a period of up to 7 days (or a creatinine clearance
decrease by .50% from baseline), then retroperito-
neal ultrasonography was performed to evaluate for
hydronephrosis. Bilateral percutaneous insertion of
a temporary nephrostomy catheter was used to relieve
obstruction in all patients, except 1 patient who had
unilateral obstruction and 1 patient who had only a sin-
gle kidney (Table 1). The median time from detection
of BKV viruria to nephrostomy tube placement was
44.5 days (range, 7-84 days). Catheters were kept in
place for a median of 38.5 days (range, 30-91 days)
and were removed after symptoms (and/or viruria)
resolved and the creatinine level returned to normal
or decreased significantly (Table 1). Creatinine val-
ues improved from a median of 3.25 mg/dL (range,
1.5-4 mg/dL) before catheter insertion to a median
of 1.1 mg/dL (range, 0.8-1.7 mg/dL) after catheter in-
sertion. Creatinine clearance also improved, from a me-
dian of 30 mL/min to 74.5 mL/min, an increase of
124% (Table 1). The median creatinine level at 4
months after catheter placement remained at 1.1 mg/
dL (range, 0.7-1.94 mg/dL) (n 5 5). No complications
Table 1. Characteristics of 6 Patients Treated with Percutaneous Nephrostomy Tube Placement for Ureteral Obstruction Associated with BKV Infection
Patient Diagnosis
Conditioning
Regimen
Donor
Type
Grade II-IV
aGVHD ±
HD Steroid
Therapy
Days from
SCT
to BK
Viruria
Cr before
BKV
Infection,
mg/dL
Days
between
BK Viruria
and Stent
Placement
Other Treatment
for BKV
Infection
Serum Cr, mg/dL CrCl, mL/min
Hydronephrosis
by US?
Cr Level 4
Months
after Stent
Placement,
mg/dL
Stent
Placement
Days
Stent
in Place
Before
Stenting
After
Stenting
Before
Stenting
After
Stenting
1 CML Flu/Bu
(RIC)
MUD GVHD: Yes
(skin); steroids: Yes
67 0.9 60 CBI 2 1.1 51 89 Yes 1.1 Bilateral 36
2 AML Flu/Bu/
plerixafor
(MA)
MUD GVHD: Yes
(skin); steroids: Yes
60 1.2 29 CBI 4 0.8 26.9 122.9 Yes 0.7 Bilateral 41
3 AML Flu/Bu
(RIC)
MUD GVHD: Yes (GI);
steroids: Yes
58 0.9 75 CBI, formalin
instillation,
cidofovir,
hyperbaric
oxygen
3 1.09 28.6 73.9 Yes* 0.8 Bilateral 30
4 MF Flu/Mel
(MA)
MUD GVHD: Yes
(skin); steroids: Yes
14 0.6 7 CBI, cidofovir 1.5 0.9 53.9 75 Yes 1.7 Unilteral 91
5 AML Flu/Mel/thiotepa
(MA)
Cord
blood
GVHD: No;
steroids: No
12 0.7 19 CBI, cidofovir, 3.9 1.3 26.8 58.3 No NA Bilateral 33
6 CLL FCR/TBI
(RIC)
Cord
blood
GVHD: No;
steroids: No
14 1.1 84 CBI, cidofovir,
bladder
fulguration,
formalin
instillation,
hyperbaric
oxygen
3.5 1.7 31.4 67.5 Yes 1.94 Unilateral 45†
AML indicates acute myelogenous leukemia; Bu, busulfan; CBI, continuous bladder irrigation; CLL, chronic lymphoblastic leukemia; CML, chronic myelogenous leukemia; Cr, creatinine; CrCl, creatinine clearance by
Cockcroft-Gault formula; FCR, fludarabine, cyclophosphamide, rituximab; Flu, fludarabine; GI, gastrointestinal; HD, high dose; MA, myeloablative; MF, mycosis fungoides; MUD, matched unrelated donor; NA, not
applicable; RIC, reduced-intensity conditioning; TBI, total body irradiation; US, ultrasound.
*The initial ultrasound showed no hydronephrosis.
†This patient had only one kidney; the catheter was capped but not removed for bladder training.
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Figure 1. Ureteral obstruction in a patient with BK viruria (A) and resolution of obstruction after percutaneous nephrostomy catheter placement (B).
1554 Biol Blood Marrow Transplant 17:1546-1568, 2011H. Khan et al.related to the catheter placement (eg, bleeding, infec-
tions, catheter malfunction or blockage) were noted
while the catheters remained in place.DISCUSSION
BKV infection is a common problem in HSCT re-
cipients. Silva et al. [15] reported that up to two-thirds
of recipients develop BKV cystitis post-HSCT. Renal
insufficiency is common in these patients; however, the
etiology is usually unclear. A rise in creatinine level and
a decline in kidney function can be attributed to a mul-
titude of factors, including primarily nephrotoxic med-
ications and intravascular volume depletion. More
rarely, BKV nephropathy is implicated. Although
BKV is by far the most common cause of hemorrhagic
cystitis after allogeneic HSCT [12], few previous re-
ports have identified the possibility of upper urinary
tract obstruction in this setting [4,16].
Here we suggest that obstructive uropathy is not an
uncommon cause of renal insufficiency in HSCT re-
cipients with BKV cystitis. Our findings demonstrate
the transient and reversible nature of this obstruction,
and suggest that temporary nephrostomy catheter
placement improves renal function and may help pre-
vent irreversible renal failure in these patients. It is im-
portant to note that none of our patients had a previous
history of nephrolithiasis or uretheral strictures,
whereas all had evidence of BKV infection of the uroe-
pithelial tract and symptoms of hemorrhagic cystitis.
Retroperitoneal ultrasound clearly showed
obstructive uropathy in 5 of our patients (83.3%).
Interestingly, the hydronephrosis was mild or mild to
moderate in all patients, suggesting that this interven-
tion was implemented before irreversible damage
could occur. Two patients initially did not have typical
findings of hydronephrosis, suggesting that hydro-
nephrosis might not be a reliable sign of early obstruc-
tion and underscoring the importance of a high levelof suspicion when assessing patients with a significant
rise in serum creatinine in the presence of BKV cystitis.
Previous pathological reports of BKV infection in
renal transplant recipients demonstrated that BKV
was harbored in ulcerated, stenosed ureters [17]. Fur-
thermore, narrowing of the ureteric lumen was linked
with localized ulceration and inflammation, with large
inclusion-bearing cells identified in the urothelium
[18]. Post-HSCT BKV-related urinary tract obstruc-
tion seems to be a more common, yet underreported,
complication of BKV infection that can lead to hydro-
nephrosis, decreased creatinine clearance, and renal
failure. In our patients, temporary ureteral nephros-
tomy catheter placement relieved the obstruction and
was followed by amarked improvement in kidney func-
tion, evidenced by an immediate doubling of creatinine
clearance, demonstrating the importance of this thera-
peutic intervention (Figure 1). The catheters remained
in place for a median time of approximately 1 month
before resolution of BKV infection. Immune function
improvement post-HSCT was generally followed by
resolution of BKV infection, decreased upper urinary
tract inflammation, and resolution of ureter stenosis.
In conclusion, our findings suggest that BKV infec-
tion may be associated with reversible upper urinary
tract obstruction that is amenable to temporary percu-
taneous nephrostomy catheter placement. Future stud-
ies should investigate the nature of this obstruction, as
well as the optimal timing of catheter placement and re-
moval, to maximize the benefits from this procedure.ACKNOWLEDGMENTS
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